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Abstract
BACKGROUND
An in vitro injury model mimicking a corneal surface injury was optimised using
human corneal epithelial cells (hCEC).
AIM
To investigate whether corneal-stroma derived stem cells (CSSC) seeded on an
amniotic membrane (AM) construct manifests an anti-inflammatory, healing
response.
METHODS
Treatment of hCEC with ethanol and pro-inflammatory cytokines were compared
in terms of viability loss, cytotoxicity, and pro-inflammatory cytokine release, in
order to generate the in vitro injury. This resulted in an optimal injury of 20%
(v/v) ethanol for 30 s with 1 ng/mL interleukin-1 (IL-1) beta. Co-culture
experiments were performed with CSSC alone and with CSSC-AM constructs.
The effect of injury and co-culture on viability, cytotoxicity, IL-6 and IL-8
production, and IL1B, TNF, IL6, and CXCL8 mRNA expression were assessed.
RESULTS
Co-culture with CSSC inhibited loss of hCEC viability caused by injury. Enzyme
linked immunosorbent assay and polymerase chain reaction showed a significant
reduction in the production of IL-6 and IL-8 pro-inflammatory cytokines, and
reduction in pro-inflammatory cytokine mRNA expression during co-culture
with CSSC alone and with the AM construct. These results confirmed the
therapeutic potential of the CSSC and the possible use of AM as a cell carrier for
application to the ocular surface.
CONCLUSION
CSSC were shown to have a potentially therapeutic anti-inflammatory effect
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when treating injured hCEC, demonstrating an important role in corneal
regeneration and wound healing, leading to an improved knowledge of their
potential use for research and therapeutic purposes.
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Core tip: We designed a novel in vitro inflammation model of the human corneal surface
using human corneal epithelial cells treated with 20% (v/v) ethanol, followed by
stimulation with 1 ng/mL interleukin-1β. We then used this model to demonstrate the
anti-inflammatory and regenerative healing properties of human cornea stroma-derived
stem cells seeded on an amniotic membrane substrate in a co-culture model. This study
is the first step in building a topical regenerative therapy for the treatment of
inflammatory disorders of the front of the eye.
Citation: Orozco Morales ML, Marsit NM, McIntosh OD, Hopkinson A, Sidney LE. Anti-
inflammatory potential of human corneal stroma-derived stem cells determined by a novel in
vitro corneal epithelial injury model. World J Stem Cells 2019; 11(2): 84-99
URL: https://www.wjgnet.com/1948-0210/full/v11/i2/84.htm
DOI: https://dx.doi.org/10.4252/wjsc.v11.i2.84
INTRODUCTION
The cornea is the transparent window of the eye. It functions to provide two thirds of
the eye’s refractive power, as well as being the major barrier to the inner content of
the eye. At present, when the cornea is damaged or diseased, transplantation of a
donor  cornea,  known as  keratoplasty,  is  the  most  effective  technique  to  restore
vision[1]. However, worldwide 8-10 million individuals have no access to a corneal
transplant.  Furthermore,  patients may suffer from rejection of allogeneic corneal
tissue or have to wait for long periods before finding a viable donor graft. For these
reasons,  corneal  research  has  turned  to  the  use  of  stem cell-based  regenerative
therapies for corneal tissue regeneration[2].
Since their discovery, mesenchymal stromal cells (MSCs) have been recognised by
different characteristics: differentiation capacity into the adipogenic, chondrogenic,
and osteogenic lineages; possible isolation from several tissues; and regeneration of
myocardial tissues, tendon, and bone, amongst others in animal models[3]. The interest
in  MSCs  has  been  enhanced  for  therapeutic  applications  due  to  their  non-
immunogenic  potential[4].  MSCs  can  be  obtained  from  autologous  tissue  and
expanded in culture, producing anti-inflammatory factors which participate in normal
wound repair[5]. Several studies have shown that MSCs have the ability to migrate to
sites of tissue injury and stop an on going immune response by inhibiting T-cell
proliferation[6].  Additionally,  MSCs  secrete  growth  factors  and  cytokines  with
autocrine and paracrine activities such as fibrosis inhibition and apoptosis, mitosis
stimulation, suppression of the local immune system, angiogenesis enhancement, and
stem cell  differentiation.  These  effects  can be  either  direct,  causing intracellular
signalling, or indirect (referred to as trophic effects), causing other cells to secrete
functionally active factors which facilitate tissue regeneration[7].
In 2008, Polisetty et al[8] demonstrated the presence of MSCs in the human corneal
limbus, which were shown to be similar to bone marrow-MSCs, indicating that these
cells are unique in the adult stem cell niche. In 2012, Branch et al[9] characterised and
analysed the peripheral and limbal corneal stromal cells, later referred to as corneal-
stroma derived stem cells (CSSC), against the criteria of the International Society of
Cellular Therapy for identification of MSCs. Finding evidence of plastic adhesion,
trilineage potential differentiation, correct profile, and expression of the cell-surface
markers, revealing that ≥ 95% of the cells expressed CD105, CD90, and CD73, but
were negative for CD11b, CD19, CD34, and HLA-DR (≤ 2%). Further characterisation
of these cells was performed to demonstrate their MSC-like phenotype in different
media and the ability to differentiate back to a keratocyte-like state[10-12].
Recent  in  vitro  studies  have  shown  that  CSSC  contribute  to  corneal  tissue
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homeostasis,  presenting  an  immunomodulatory  response,  a  non-immunogenic
profile,  and a regenerative role[13-15].  From this,  we can infer that these cells have
potential  to  control  the  microenvironment  during  local  inflammation,  and  are
candidates  for  allogeneic  cell-based  therapies.  There  have  been  several  studies
investigating the use of MSCs from other tissue (bone marrow or adipose tissue) in
treating corneal disease to differing success[16-19]. The use of MSCs from tissues other
than the cornea has shown limitations for corneal disease models. In 2015, Fuentes-
Julián et al[20]  aimed to prevent transplant rejection with an adipose-derived MSC
treatment  while  increasing  the  length  of  graft  survival  in  a  rabbit  corneal
inflammation model. However, the treatment had the opposite effect and increased
the inflammation. Additionally, it is well known that even if MSCs share biological
functions and molecular expression profiles across different tissues, they retain a
differentiation preference due to their tissue origins[21]. Thus, corneal-derived MSCs,
such  as  CSSCs,  may  be  considered  a  more  appropriate  cell  source  for  corneal
regeneration.
The amniotic membrane (AM) is the inner most membrane encapsulating the foetus
in the amniotic cavity, and consists of a simple epithelium, avascular stroma, and
basement membrane[22]. The first therapeutic application of AM was reported in 1913
as  a  surgical  procedure  for  skin [23].  In  the  1940s,  AM  was  first  used  in  the
ophthalmology field as a patch to cover defects in the conjunctival epithelium[24].
Subsequently, several studies have demonstrated that AM maintains an anti-scarring
and anti-inflammatory  action  during  pregnancy[25],  providing  evidence  of  these
properties for ocular disorders[26,27]. Alongside its therapeutic properties, AM has been
widely used as a cell carrier for different conditions such as chemical burns, ocular
cicatricial  pemphigoid,  severe  pterygium,  and  Stevens-Johnson  syndrome[28,29],
providing an effective cell-delivery method and a more effective therapeutic effect[30].
In this study, the optimization of an in vitro  injury model based on 20% (v/v)
ethanol (EtOH) and pro-inflammatory cytokine stimulation has been performed using
an immortalised human corneal epithelial cell (hCEC) line with the aim of assessing
the therapeutic potential of both the CSSC and the AM in a co-culture system by
performing the following analyses: cell viability, cytotoxicity, interleukin (IL)-6, IL-8
production, and quantitative reverse transcription polymerase chain reaction (RT-
qPCR) for the genes IL1B, TNF, IL6, and CXCL8.
MATERIALS AND METHODS
Human tissue
Human  corneoscleral  rims  and  human  AM  were  used  with  approval  by  the
Nottingham Research Ethics Committee (07/H0403/140 and OY110101, respectively)
and in accordance with the tenets of the Declaration of Helsinki. Informed consent
was obtained from the donors and/or their relatives.
Culture of immortalised human corneal epithelial cells
SV40-immortalised  human  corneal  epithelial  cells  (hCEC)[31]  were  cultured  in
supplemented basal epithelial cell medium EpiLife® (Gibco, ThermoFisher, United
Kingdom)  containing  5  mL  human  keratinocyte  growth  supplement  (Gibco,
ThermoFisher) and 1% (v/v) antibiotic-antimycotic (AbAm, Sigma-Aldrich, United
Kingdom). Cells were incubated at 37 °C, 5% CO2  (standard conditions),  and the
medium changed every 2-3 d. hCEC were passaged at approximately 80% confluency
using TrypLE Express dissociation reagent (ThermoFisher). hCEC were used between
passages 24-31 and seeded at 5 × 104 cell/cm2 density.
Isolation and culture of CSSC
CSSC were  isolated  as  previously  described[11].  Briefly,  corneoscleral  rims  were
washed with PBS containing 1% (v/v) AbAm. Residual sclera was removed with a
scalpel and the rim was cut in small pieces, placed into 1 mg/mL collagenase type IA
(Sigma-Aldrich) solution in basal medium 199 (M199) with 1% (v/v) AbAm, before
incubation at 37 °C under slow agitation for 7 h. Digests were filtered through a 40 µm
cell-strainer to remove debris and the cells seeded in appropriate culture medium.
Culture medium either consisted of M199 (Sigma-Aldrich) supplemented with 20%
(v/v) foetal bovine serum (Sigma-Aldrich), 1% (v/v) L-Glutamine (Sigma-Aldrich),
and 1% (v/v) AbAm or stem cell medium (SCM) consisting of Dulbecco’s modified
Eagle’s medium: nutrient mixture F-12 (Gibco, ThermoFisher) supplemented with
20% (v/v) knockout serum replacement (Gibco, ThermoFisher), 1% (v/v) MEM non-
essential amino acids (Gibco, ThermoFisher), 4 ng/mL basic-fibroblast growth factor
(Gibco), 5 ng/mL human leukaemia inhibitory factor (Cell Signalling Technologies,
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United Kingdom), and 1% (v/v) AbAm. Finally, the cell suspension was transferred
to a 0.1% (v/v) bovine gelatine (Sigma-Aldrich) coated T25 cm2 flask and incubated at
standard  conditions.  Medium  was  changed  every  3-4  d.  CSSC  passaging  was
performed  using  TrypLE  Express  dissociation  reagent  and  cells  were  used
experimentally between passages 4-6 and seeded at 2 × 104 cell/cm2 density, unless
otherwise stated.
Experimental culture medium
To assess optimal growth conditions for co-culture of hCEC with CSSC, four media
were  tested:  M199,  SCM,  EpiLife  supplemented  as  previously  mentioned,  and
keratinocyte-serum free medium (K-SFM, Gibco, ThermoFisher) supplemented with
keratinocyte supplement (bovine pituitary extract, epidermal growth factor) and 1%
(v/v) AbAm.
Cell viability and proliferation assay
PrestoBlue Cell Viability Reagent (Invitrogen, ThermoFisher) was used to assess cell
viability and proliferation. At each time point, culture medium was removed from the
cells and a 10% (v/v) PrestoBlue solution in Hank’s balanced salt solution was added
to each well before incubation for 30 min at 37 °C. Aliquots of 100 µL from each well
were transferred to a black 96-well plate and fluorescence readings were taken at 560
nm excitation/590 nm emission with a CLARIOstar microplate reader (BMG LabTech,
Buckinghamshire,  United  Kingdom).  Results  were  corrected  for  background
fluorescence from blank readings.
Injury model optimisation
The effect of combinations of the following conditions were assessed on the hCEC:
treatment with 20% (v/v) absolute ethanol (EtOH) in PBS for 30 seconds; application
of 1 ng/mL human IL-1β (R and D Systems, United Kingdom) in the media and/or
application of 10 ng/mL human tumour necrosis factor (TNF)-α (R and D Systems,
United Kingdom). The effect of culturing with IL-1β and TNF-α was assessed on the
CSSC. The final injury model used in further co-culture studies consisted of treatment
of the hCEC with 20% EtOH for 30 s followed by incubation with 1 ng/mL IL-1β.
CSSC were not treated with EtOH during any experiments.
Cytotoxicity
The Pierce lactate dehydrogenase (LDH) Cytotoxicity Assay Kit (ThermoScientific,
United Kingdom) was used to quantify cytotoxicity caused by the injury model by
measuring LDH release into the culture medium. The assay was performed according
to the manufacturer’s protocol. Briefly, 50 µL of cell supernatant and 50 µL of reaction
mixture were transferred into a 96-well plate, and incubated at room temperature for
30  min.  The  optical  absorbance  was  read  on  the  plate  reader  at  490  nm  with
background  correction  at  690  nm.  Data  was  converted  to  a  percentage  using  a
maximum  LDH  release  control  reading  to  create  a  percentage  cytotoxicity  and
corrected for cell viability.
Cytokine production
Human IL-6 and CXCL8/IL-8 DuoSet enzyme linked immunosorbent assay (R and D
Systems, Abingdon, United Kingdom) were used in combination with the appropriate
DuoSet  Ancillary  Reagent  Kit  (R  and  D  Systems),  according  to  manufacturer’s
instructions, to detect cytokine protein levels in a sample. Briefly, the supernatant
samples were diluted 1:20. Optical density at 450 nm with background correction at
540 nm was determined immediately after the addition of the stop solution. Cytokine
concentration was determined using 4-parameter fit standard. Data was corrected for
the number of cells using viability data.
LIVE/DEAD™ viability assay
The LIVE/DEAD viability kit for mammalian cells (Invitrogen, ThermoFisher) was
used  to  simultaneously  stain  live  (green)  and  dead  (red)  cells  after  injury  was
performed.  hCEC  were  seeded  in  8-well  Permanox  Lab-Tek  chamber  slides
(ThermoFisher Scientific). Cell monolayers were incubated with a solution containing
2 µmol/L calcein AM and 4 µmol/L ethidium homodimer-1 in PBS for 30 min. After
incubation,  the  staining  solution  was  discarded,  chambers  removed,  and slides
mounted under coverslips in fluorescent mounting media (Dako, United Kingdom).
Imaging was performed using an upright fluorescence microscope (BX51, Olympus,
Southend-on-Sea, United Kingdom) with images captured with a black and white
camera (XM-10, Olympus) and Cell^F software (Olympus).
Collection of conditioned medium
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Conditioned medium was collected from CSSC at  P4 cultured in SCM and SCM
supplemented with 1 ng/mL IL-1β. CSSC were seeded at 10000 cells/cm2 in T75 cm2
flasks. Conditioned medium was produced by adding 12 mL appropriate media and
culturing for 72 h, before collection and filtering through a 0.22 µm filter.
Co-culture
hCEC were seeded in 12-well plates at a density of 5 × 104 cell/cm2 and CSSC were
seeded separately at 2 × 104 cell/cm2 into 12 mm transwells with 0.4 µm polyester
membrane insert (Corning). On the day of the injury model, hCEC were treated with
20% (v/v) EtOH for 30 s, prior to the CSSC-seeded transwells being added to the co-
culture. SCM containing 1 ng/mL IL-1β was then added to cover both cell types.
Controls for co-culture experiments included no injury, hCEC only, and CSSC only to
correct for background production.
RT-qPCR
RT-qPCR was performed as previously described[10]. Briefly, RNA was extracted from
cells using an RNeasy mini kit (Qiagen, Manchester, United Kingdom) according to
manufacturer’s instructions and quantified using an LVis-plate in a CLARIOstar plate
reader. RNA transcription to single-stranded cDNA synthesis was performed with 1
µg of the total RNA using the SuperScript III First Strand Synthesis Kit (Invitrogen,
ThermoFisher)  using  random  hexamers.  For  PCR,  1  µL  cDNA  was  used  with
inventoried TaqMan assays (Applied Biosystems, ThermoFisher) to detect GAPDH
(Hs99999905_m1),  IL1B  (Hs01555410_m1),  TNF  (Hs00174128_m1),  IL6
(Hs00985639_m1), and CXCL8 (Hs00174103_m1). Gene amplification was performed
on an Mx3005P multi-colour 96-well PCR-system (Stratagene, Agilent Technologies).
Results  were  analysed with the  RT-qPCR Miner  algorithm[32].  All  readings  were
normalised using the endogenous reference gene GAPDH.
CSSC-AM construct preparation
Preparation  of  the  dried,  vacuum-packed  AM  was  performed  as  previously
described[33]. Briefly, AM was separated from chorion and triple washed in sodium
chloride, before the spongy layer was removed. After incubation in 100 mmol/L
raffinose pentahydrate (Acros Organics, United Kingdom) in PBS for 2 h, the AM was
dried with main drying at a shelf temperature of 15 °C, vacuum 1.03 mbar for 30 min,
followed by a final drying phase, shelf temperature 15 °C, vacuum pressure 0.001
mbar for 15 min in a cooled freeze dryer (Alpha 1-4 LSC, Advanced Freeze Dryer,
Christ Osterode, Germany).
To culture CSSC on AM, a novel method designed in our laboratory was employed
(Figure 1).  Single  use  30  mm diameter  Millicell  tissue culture  inserts  (Millipore,
United  Kingdom)  were  used  without  filtration  membranes.  A  sterilisable
polytetrafluoroethylene  O-ring  was  placed  in  the  centre  of  a  5  cm  diameter
rehydrated AM, epithelial side up. The AM was then trimmed to create a 1 cm frill
around the inside of the O-ring, which was subsequently firmly wrapped over the O-
ring edges creating a taut wrinkle free-surface. Forceps were used to position the O-
ring-AM construct into the Millicell insert and the O-ring-AM construct was then
gently pushed by the edges to the bottom. The AM-insert was placed in a 6-well tissue
culture plate and the AM soaked in culture medium overnight. CSSC were seeded on
the AM construct 7 d before inducing the injury model. On a separate 6-well plate,
hCEC were seeded at 5 × 104 cell/cm2 density 72 h before injury. On the injury day,
the hCEC were treated with 20% (v/v) EtOH for 30 s, the CSSC-AM constructs were
moved into the wells  for  co-culture studies  and SCM containing 1 ng/mL IL-1β
added. Controls for CSSC-AM co-culture experiments included no-injury, hCEC only,
CSSC only, and AM only.
Statistical analysis
Statistical significances were calculated using GraphPad Prism v.7.00.
RESULTS
M199 and SCM support both hCEC and CSSC viability and proliferation
To determine an optimal medium for co-culturing hCEC and CSSC, both cell types
were cultured in EpiLife, K-SFM, M199, and SCM with viability assays performed at
24 h and 144 h (Figure 2). hCEC showed significant proliferation in EpiLife, SCM, and
M199 (Figure 2A). Contrary to expectations, hCEC in K-SFM did not proliferate. CSSC
only demonstrated significant proliferation in SCM, but did not lose viability in M199.
Culture in EpiLife and K-SFM significantly reduced CSSC viability (Figure 2B). As
M199 and SCM supported both cell  types,  both media  were  selected for  further
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Figure 1
Figure 1  Culture system enabling seeding of corneal-stroma derived stem cells on amniotic membrane. A: Schematic showing dimensions and arrangement
of polytetrafluoroethylene (PTFE) O-ring inside 30 mm tissue culture insert; B: The PTFE ring is placed on the epithelial side of hydrated amniotic membrane (AM); C:
The AM is firmly wrapped over the O-ring edges leaving a taut membrane surface for cell seeding; D: The O-ring containing the AM is placed within the tissue culture
insert; E: The tissue culture insert is placed within a 6-well plate and culture medium applied.
experiments.
An injury model of 20% (v/v) EtOH and 1 ng/mL IL-1β creates a balance between cell
viability reduction and pro-inflammatory cytokine production
Different combinations of EtOH injury with and without inflammatory stimulus were
tested on hCEC cultured in SCM and M199 to determine an optimised injury model
(Figure 3).  Viability assays were performed 72 h after injury with/without IL-1β
and/or TNF-α supplementing the culture medium for the entire time (Figure 3A and
3B). For cells cultured in M199, all injury treatments caused significant reductions in
cell  viability,  with  EtOH  with  IL-1β  and  TNF-α  treatment  causing  the  largest
reduction (Figure 3A). For cells cultured in SCM, there was no significant drop in
viability when cells were treated with only IL-1β; the remaining treatments all caused
over  50%  reduction  in  viability  (Figure  3B)  with  EtOH  with  IL-1β  and  TNF-α
treatment causing the largest reduction.
Cytotoxicity caused by the injury was measured by levels of the LDH enzyme
within the supernatant 72 h after injury began (Figure 3C and 3D). In both M199 and
SCM, only treatment with EtOH with IL-1β, or EtOH with IL-1β and TNF-α caused
significant levels  of  cytotoxicity compared with the no injury controls.  Levels of
inflammation within the injury models were assessed by measuring IL-6 and IL-8
concentration within the hCEC supernatant 72 h after initial injury (Figure 3E, 3F, 3G,
and 3H). Significant concentrations of IL-6 were found with treatment of EtOH with
IL-1β, or EtOH with IL-1β and TNF-α in both M199 (Figure 3E) and SCM (Figure 3F).
IL-8 production was only significant in M199 when treated with EtOH with IL-1β and
TNF-α (Figure 3G), but in SCM was significant when treated with EtOH with IL-1β, or
EtOH with  IL-1β  and  TNF-α  (Figure  3H).  Representative  LIVE/DEAD staining
images of hCEC cultured in SCM 72 h after initial injury can be seen in Figure 3I.
When EtOH treatment was not used, 1 ng/mL IL-1β treatment showed an almost
comparable cell confluence to the control. All other treatments evidenced a decrease
in cell number, with EtOH with IL-1β and TNF-α being the most toxic.
These results taken as a whole suggest that combining EtOH treatment with both
IL-1β and TNF-α generates high, but unnecessary, inflammatory and toxic damage to
the cells, leaving few cells alive for further analysis. The most balanced treatment was
20% (v/v) EtOH with 1 ng/mL IL-1β, which led to significant production of pro-
inflammatory cytokines, significant cytotoxicity, and a significant but not excessive
reduction in viability. Thus, this injury model was chosen for further experiments. It
was also decided to continue co-culture experiments in SCM only.
CSSC viability remains stable after treatment with IL-1β but production of IL-6 and
IL-8 is increased
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Figure 2
Figure 2  Effect of culture medium on human corneal epithelial cells and corneal-stroma derived stem cells viability and proliferation. A, B: Human corneal
epithelial cells (A) and corneal-stroma derived stem cells (B) were seeded in EpiLife, keratinocyte-serum free medium, stem cell medium, and M199. Presto Blue
viability assay was performed at 24 h and 144 h. Each time point is represented relative to the viability in that media type at 24 h. Data shown as mean ± SEM of six
replicates (n = 6) each with 3 samples. Statistical significance compared to 24 h, analysed by two-way ANOVA, represented by bP ≤ 0.0001. CSSC: Corneal-stroma
derived stem cells; hCEC: Human corneal epithelial cells; K-SFM: Keratinocyte-serum free medium; SCM: Stem cell medium.
CSSC cultured in both M199 and SCM were stimulated with IL-1β and TNF-α and
assessed with identical assays to those described above, in preparation for co-culture
with hCEC (Figure 4). Viability assays were performed at 72 h of cytokine stimulation
(Figure 4A and 4B).  A significant reduction in viability compared to non-injured
controls was seen when IL-1β and TNF-α together were present in the medium. LDH
concentration in the media, indicating cytotoxicity, was assessed after 72 h stimulation
(Figure 4C and 4D). Significant cytotoxicity was only seen in M199 when treated with
both IL-1β and TNF-α. Assessment of IL-6 (Figure 4E and 4F) and IL-8 (Figure 4G and
4H) production showed significant production of IL-6 in both media due to IL-1β
treatment alone and with TNF-α. IL-8 was produced in significant levels in SCM due
to IL-1β treatment alone and with TNF-α but only in M199 when both cytokines were
present.  Overall  production of IL-6 and IL-8 by CSSC was far lower than that of
hCEC.
CSSC conditioned medium does not inhibit hCEC viability loss but shows some
inhibition of LDH, IL-6, and IL-8 production after injury.
CSSC were used to obtain conditioned SCM medium in order to determine if secreted
factors alone were adequate for producing an anti-inflammatory response. hCEC
were injured with EtOH for 30 s.  Subsequently,  SCM control,  CSSC-conditioned
medium, or CSSC-conditioned medium pre-treated with IL-1β were applied along
with the extra IL-1β inflammatory stimulus for 72 h before analysis (Figure 5). No
inhibition in  the  reduction of  viability  due to  the  injury was seen in  any group,
although there was significant reduction in viability of non-injured hCEC due to the
presence of conditioned medium (Figure 5A). There was significant reduction in the
levels  of  cytotoxicity  caused  by  the  injury  with  treatment  with  both  types  of
conditioned  medium,  however  there  was  still  significant  levels  of  cytotoxicity
compared to non-injured controls (Figure 5B). There was significant reduction in the
production of IL-6 by injured hCEC when treated with CSSC-conditioned medium
with and without IL-1β pre-treatment; however, levels were still significantly higher
than non-injured controls (Figure 5C). IL-8 production by hCEC in response to injury
was not significant compared to the non-injured control when treated with CSSC-
conditioned medium. However, when treated with the conditioned medium from the
CSSC that had IL-1β pre-treatment, there was a significant increase in the levels of IL-
8, potentially due to the high levels of IL-1β (Figure 5D).
Co-culture of CSSC with injured hCEC improves hCEC viability and reduces post-
injury inflammation
hCEC were treated with the standard injury of  EtOH for 30 s  followed by IL-1β
stimulation. During the IL-1β treatment, co-cultures of CSSC were added and analysis
of viability, cytotoxicity, cytokine production, and gene expression were performed
after 72 h (Figure 6). There was a significant reduction in viability of the injured hCEC
compared to non-injured cells, as previously shown. However, the addition of the
CSSC  in  co-culture  to  the  injured  hCEC  showed  a  significant  inhibition  of  this
viability decrease, with a significantly higher viability shown in the co-culture injured
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Figure 3
Figure 3  Injury model optimisation for human corneal epithelial cells. Injury model optimisation was performed with human corneal epithelial cells (hCEC)
cultured in both M199 (A, C, E, G) and stem cell medium (B, D, F, H). Injuries consisted of the following treatments: 20% (v/v) ethanol (EtOH); 1 ng/mL interleukin (IL)-
1β in the medium; 20% (v/v) EtOH with 1 ng/mL IL-1β in the medium; and 20% (v/v) EtOH with 1 ng/mL IL-1β and 10 ng/mL TNF-α in the medium. A, B: PrestoBlue
viability assay performed 72 h after the different treatments. Data represented relative to reading for no injury control; C, D: LDH assay performed on supernatant 72 h
after injury. Data displayed as percentage cytotoxicity and relative to cell viability; E, F: Concentration of IL-6 in the supernatant 72 h after injury. Data displayed
relative to cell viability; G, H: Concentration of IL-8 in the supernatant 72 h after injury. Data displayed relative to cell viability. Data for all graphs shown as mean ±
SEM of five independent experiments, with three to six replicates each. Statistical significance compared to no injury controls analysed by one-way ANOVA
represented by aP ≤ 0.05, bP ≤ 0.01, dP ≤ 0.001, fP ≤ 0.0001; I: LIVE/DEAD staining performed on hCEC cultured in stem cell medium for hCEC untreated control
(A), 20% (v/v) EtOH (B), 1 ng/mL IL-1β (C), EtOH + 1 ng/mL IL-1β (D), EtOH + 10 ng/mL IL-1β (E), and EtOH+ 1 ng/mL IL-1β + 10 ng/mL TNF-α (F). Live staining
(green) is shown with FITC, and dead staining (red) is shown with TRITC. Scale bar = 100 µm. hCEC: Human corneal epithelial cells; IL: Interleukin; SCM: Stem cell
medium; TNF: Tumour necrosis factor.
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Figure 4
Figure 4  Effect of treatment with pro-inflammatory cytokines on corneal-stroma derived stem cells. Treatment of corneal-stroma derived stem cells cultured in
stem cell medium or M199 with 1 ng/mL IL-1β with/without 10 ng/mL tumour necrosis factor-α was performed for 72 h. A: PrestoBlue viability assay after 72 h
stimulation. Data represented relative to reading for no injury control; B: Lactate dehydrogenase cytotoxicity assay performed on cell supernatants after 72 h
treatment. Data displayed as percentage cytotoxicity and relative to cell viability; C: Concentration of IL-6 in the supernatant 72 h after injury. Data displayed relative to
cell viability; D: Concentration of IL-8 in the supernatant 72 h after injury. Data displayed relative to cell viability. Data for all graphs shown as mean ± SEM of five
independent experiments with three to six replicates each. Statistical significance compared to no injury controls analysed by one-way ANOVA represented by aP ≤
0.05, bP ≤ 0.01, dP ≤ 0.001, fP ≤ 0.0001. IL: Interleukin; TNF: Tumour necrosis factor; SCM: Stem cell medium.
group than in non-co-culture (Figure 6A). Levels of cytotoxicity were significantly
reduced in the co-culture systems when compared to hCEC only, with no significant
difference shown between no injury and injury (Figure 6B). Both IL-6 (Figure 6C) and
IL-8 (Figure 6D) production was significantly reduced when in co-culture compared
to the hCEC only injured group. Gene expression of IL1B (Figure 6E), IL6 (Figure 6G)
and CXCL8 (IL-8, Figure 6H) by injured hCEC was also significantly reduced by co-
culture with CSSC. TNF expression was not significantly reduced (Figure 6F).
Co-culture of injured hCEC with the CSSC-AM construct improves hCEC viability
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Figure 5
Figure 5  Effect of corneal-stroma derived stem cells-conditioned medium on human corneal epithelial cells treated with the injury model. Human corneal
epithelial cells (hCEC) were treated with an injury model consisting of 30 s ethanol treatment followed by stimulation with 1 ng/mL IL-1β for 72 h. Medium conditioned
by corneal-stroma derived stem cells with and without pre-treatment with IL-1β was applied to the hCEC after ethanol treatment during stimulation with IL-1β. A:
PrestoBlue viability assay after 72 h. Data represented relative to reading for hCEC no injury control; B: Lactate dehydrogenase cytotoxicity assay performed on cell
supernatants after 72 h treatment. Data displayed as percentage cytotoxicity and relative to cell viability; C: Concentration of IL-6 in the supernatant 72 h after injury.
Data displayed relative to cell viability; D: Concentration of IL-8 in the supernatant 72 h after injury. Data displayed relative to cell viability. Data shown as mean ±
SEM of three independent experiments with four to six replicates each. Statistical significance analysed by two-way ANOVA. Significance compared to non-injured,
same treatment represented by aP ≤ 0.05, bP ≤ 0.01, dP ≤ 0.0001. Significance compared to hCEC, no injury represented by cP ≤ 0.05, fP ≤ 0.01, hP ≤ 0.0001.
Significance compared to hCEC, injury represented by eP ≤ 0.05, jP ≤ 0.01, nP ≤ 0.001, lP ≤ 0.0001. hCEC: Human corneal epithelial cells; IL: Interleukin.
while reducing pro-inflammatory cytokines and pro-inflammatory cytokine mRNA
expression after injury
hCEC were treated with the standard injury of EtOH followed by IL-1β stimulation in
the culture medium. During the IL-1β stimulation, constructs of AM only and CSSC-
AM were added in co-culture. After 72 h, analysis of viability, cytotoxicity, cytokine
production, and mRNA expression of the hCEC were performed (Figure 7). As seen
previously, there was a loss in hCEC viability when the injury was performed without
co-culture. This loss in viability was not inhibited by the presence of AM alone, but
significant inhibition of viability loss was demonstrated when injured hCEC were co-
cultured with the CSSC-AM construct (Figure 7A). Increased cytotoxicity was seen
when hCEC were  injured without  co-culture;  this  was  not  inhibited  by  the  AM
construct, but was significantly inhibited by co-culture with the CSSC-AM construct
(Figure 7B).  IL-6  and IL-8 release into the media due to  injury was significantly
inhibited during co-culture with the CSSC-AM construct (Figure 7C and 7D). IL-8
production was also significantly inhibited by the presence of AM only. Unlike, the
previous co-culture experiment, expression of IL1B was not significantly reduced by
either co-culture during injury (Figure 7E). Expression of TNF was also unaffected by
co-culture (Figure 7F). Expression of IL6 (Figure 7G) and CXCL8 (IL-8, Figure 7H)
mRNA were significantly reduced when injured hCEC were co-cultured with CSSC-
AM. This reduction did not occur with AM only.
DISCUSSION
In  the  last  few  decades,  MSCs  have  been  widely  studied  for  viable  medical
applications due to their therapeutic properties[34,35].  Moreover, CSSC have a huge
potential in the ophthalmology field as these stem cells may play an important role in
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Figure 6
Figure 6  Effect of co-culture with corneal-stroma derived stem cells on human corneal epithelial cells response after injury. Human corneal epithelial cells
(hCEC) were treated with an injury model consisting of 30 s ethanol treatment followed by stimulation with 1 ng/mL IL-1β for 72 h. During IL-1β stimulation corneal-
stroma derived stem cells (CSSC) were co-cultured with CSSC in a transwell system. A: PrestoBlue viability assay after 72 h. Data represented relative to reading for
hCEC only, no injury control; B: Lactate dehydrogenase cytotoxicity assay performed on cell supernatants after 72 h treatment. Data displayed as percentage
cytotoxicity and relative to cell viability; C: Concentration of IL-6 in the supernatant 72 h after injury. Data displayed relative to cell viability; D: Concentration of IL-8 in
the supernatant 72 h after injury. Data displayed relative to cell viability; E-H: RT-qPCR performed to show mRNA expression of IL1B (E), TNF (F), IL6 (G), and
CXCL8 (H). Expression of each target gene normalised to GAPDH and represented relative to hCEC only, no injury. Data for all graphs shown as mean ± SEM of
three independent experiments with five replicates each. Statistical significance analysed by two-way ANOVA. Significance compared to non-injured, same group,
represented by aP ≤ 0.05, bP ≤ 0.01, dP ≤ 0.001, fP ≤ 0.0001. Significance compared to hCEC only, no injury represented by cP ≤ 0.05, hP ≤ 0.01, jP ≤ 0.001, lP ≤
0.0001. Significance compared to hCEC, injury represented by eP ≤ 0.05, nP ≤ 0.01, vP ≤ 0.001, xP ≤ 0.0001. CSSC: Corneal-stroma derived stem cells; hCEC:
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Human corneal epithelial cells; IL: Interleukin.
corneal regeneration and wound healing[36]. Some of their important functions are the
transdifferentiation capacity from the mesenchymal to the epithelial phenotype[15,37]
and the generation of progenitors with MSC potential[38].
Although CSSC provide positive results as therapy for sight-threatening corneal
diseases[14],  an optimal cell-delivery format is essential for a cell-based therapy to
succeed.  The choice  of  the  delivery method depends on both the  tissue  and the
disease to be treated, looking for a high cell retention and integration capacity for the
cells to repopulate, release healing factors, or help the surrounding tissues and cells to
recover their normal functions[39]. For corneal disease, AM shows high promise as a
biocompatible scaffold, demonstrating properties which enhance the delivery of a
cell-based therapy to the eye’s surface through a topical application[26,30].
Herein, a comparison between four injury models was undertaken on hCEC to
generate an in vitro model to mimic a keratitis condition in the cornea with the aim of
demonstrating the therapeutic potential of CSSC. The second stage was to build a
construct  of  CSSC  on  AM  to  investigate  if  the  CSSC  maintained  their  anti-
inflammatory properties when using the membrane as a carrier and to discern if the
AM added extra anti-inflammatory value.
Several factors had to be considered to develop a functional inflammatory model.
Firstly, the comparison between K-SFM, EpiLife, SCM, and M199 took place in order
to  provide  an  optimal  growth  environment  for  both  hCEC and CSSC when co-
cultured. EpiLife is serum-free and commercially available for human epidermal
keratinocytes, and it has been previously used and approved for hCEC culture[40]. K-
SFM is another serum-free medium for epithelial cells, supplemented with epidermal
growth factor and basic-fibroblast growth factor, which has been shown to be efficient
for keratocyte[41]  and hCEC[42]  maintenance and proliferation.  M199 was the only
serum-containing medium tested in this study and it has previously demonstrated to
maintain an MSC-like cell-surface marker profile when culturing CSSC[9,12]. Finally,
SCM is mostly related with induced pluripotent stem cells and human embryonic
stem cells. It contains basic-fibroblast growth factor, human leukaemia inhibitory
factor,  and  knockout  serum  replacement  and  has  been  associated  with  the
maintenance of pluripotency markers in CSSC cultures[10]. In this investigation, SCM
and  M199  maintained  the  proliferation  and  viability  for  both  hCEC  and  CSSC,
confirming previous studies performed on CSSC by our research group. However, as
the ultimate outcome for this research is to translate the investigation into a cell-
therapy based on maintenance and viability  of  the CSSC to heal  the cornea and
recover vision, an FBS-containing medium is not appropriate due to its variability in
composition from batch-to-batch and its animal origin[43]. Moreover, despite the fact
that M199 accomplished the minimal criteria for maintaining an MSC phenotype it
does not share the advantages of SCM for the promotion of SC/progenitor markers
while  maintaining  a  MSC  phenotype.  Therefore,  SCM  is  the  best  prospect  for
therapeutic applications[10].
Four models were initially tested against the hCEC to generate an injury. The 1
ng/mL IL-1β only treatment was not potent enough to significantly reduce the cell
proliferation and it did not develop effective levels of inflammation. This response is
supported by studies showing that IL-1β promotes differentiation of progenitor cells
as well as maturation and survival of differentiated cells[44,45]. Treatment of 20% (v/v)
EtOH only significantly reduced the cell viability/proliferation and caused an initial
injury as supported by previous studies[46]. However, it did not activate the cells to
generate  inflammation  through  production  of  pro-inflammatory  cytokines.  In
contrast, the IL-1β and TNF-α treatments both generated an inflammatory response.
Combining both cytokines was too aggressive, allowing only a few cells to recover for
further  analysis.  On  the  other  hand,  the  20%  (v/v)  EtOH  with  1  ng/mL  IL-1β
treatment provided a balance between injury and inflammatory response, proving to
be the optimal injury model to mimic an in vitro  keratitis model. This outcome is
consistent with the reviewed literature, as the inflammatory properties of IL-1β and
TNF-α had only been tested individually[47,48]. However, to the best of the author’s
knowledge  this  was  the  first  time  that  these  combinations  were  used  for  the
generation of an in vitro injury model.
CSSC-conditioned medium was used on the hCEC injury model to assess potential
anti-inflammatory action.  The conditioned medium showed no significant  effect
improving hCEC viability, but did demonstrate some positive effects by reducing
cytotoxicity and IL-6/IL-8 production, demonstrating that CSSC secrete factors into
the media that have a positive anti-inflammatory effect.
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Figure 7
Figure 7  Effect of co-culture with corneal-stroma derived stem cells-amniotic membrane constructs on human corneal epithelial cells response after
injury. Human corneal epithelial cells (hCEC) were treated with an injury model consisting of 30 s ethanol treatment followed by stimulation with 1 ng/mL IL-1β for 72
h. During IL-1β stimulation hCEC were co-cultured with either amniotic membrane (AM) only or a corneal-stroma derived stem cells-AM construct. A: PrestoBlue
viability assay after 72 h. Data represented relative to reading for hCEC only, no injury control; B: Lactate dehydrogenase cytotoxicity assay performed on cell
supernatants after 72 h treatment. Data displayed as percentage cytotoxicity and relative to cell viability; C: Concentration of IL-6 in the supernatant 72 h after injury.
Data displayed relative to cell viability; D: Concentration of IL-8 in the supernatant 72 h after injury. Data displayed relative to cell viability; E-H: RT-qPCR performed to
show mRNA expression of IL1B (E), TNF (F), IL6 (G), and CXCL8 (H). Expression of each target gene normalised to GAPDH and represented relative to hCEC only,
no injury. Data for all graphs shown as mean ± SEM of three independent experiments with five replicates each. Statistical significance analysed by two-way ANOVA.
WJSC https://www.wjgnet.com February 26, 2019 Volume 11 Issue 2
Orozco Morales ML et al. Anti-inflammatory potential of corneal stromal stem cells
96
Significance compared to non-injured, same group, represented by aP ≤ 0.05, bP ≤ 0.01, dP ≤ 0.0001. Significance compared to hCEC only, no injury represented by
cP ≤ 0.05, fP ≤ 0.01, hP ≤ 0.001, jP ≤ 0.0001. Significance compared to hCEC, injury represented by eP ≤ 0.05, lP ≤ 0.01, nP ≤ 0.001, vP ≤ 0.0001. AM: Amniotic
membrane; CSSC: Corneal-stroma derived stem cells; hCEC: Human corneal epithelial cells; IL: Interleukin.
Both the CSSC alone and the CSSC-AM constructs inhibited the hCEC viability loss
seen when the injury was performed. Furthermore, both systems showed beneficial
anti-inflammatory  effects  as  production  of  pro-inflammatory  cytokines,  pro-
inflammatory mRNA expression, and cytotoxicity levels were significantly reduced.
The beneficial therapeutic effect of the CSSC was further evidenced by the fact that
the  AM  construct  without  CSSC  had  few  inhibitory  effects  on  the  injury.
Investigations for similar constructs have been performed before with positive results;
Li et al[49] developed a construct where corneal stroma and limbal epithelium with SCs
promoted cell proliferation. Additionally, a model using real architecture for 3D-
tissue tissue equivalents as a substrate for co-culturing limbal epithelial cells and
CSSC  showed  a  positive  impact  on  the  expansion  of  the  epithelial  cells  while
maintaining the MSC-markers CD73 and CD90, confirming the CSSC phenotype[50].
Contrary to our findings, previous work on burned rat corneas showed that MSCs
increased IL6 expression but still reduced corneal inflammation[51].
In conclusion, an in vitro injury model was developed using hCEC culture, allowing
the initial testing into the anti-inflammatory potential of CSSC. However, it is well
known that in vitro observations are not always able to reflect an in vivo phenomenon;
it would therefore be necessary to validate these findings in preclinical animal models
in  order  to  validate  efficacy  to  proceed  to  clinical  trials.  Nevertheless,  this
investigation demonstrated that CSSC have an important role in corneal regeneration
and wound healing and is a stepping stone towards further preclinical investigation.
ARTICLE HIGHLIGHTS
Research background
The cornea provides two thirds of the eye’s refractive power as well as being the major barrier to
the inner content of the eye. At present, the most effective treatment of a diseased or damaged
cornea is transplantation of a donor cornea (keratoplasty). However, this is not feasible for 8-10
million individuals.  Corneal research has turned to the use of stem cell-based regenerative
therapies for corneal tissue regeneration. Recent in vitro studies have shown that mesenchymal
stem cell-like cells from the corneal stroma (corneal-derived stromal stem cells, CSSC) contribute
to corneal tissue homeostasis, presenting an immunomodulatory response, a non-immunogenic
profile, and a regenerative role. Thus, CSSC may be considered an appropriate cell source for the
treatment of inflammatory disorders of the cornea.
Research motivation
To investigate whether CSSC seeded on an amniotic membrane (AM) substrate have the ability
to modulate an inflamed environment, and therefore whether they were suitable candidates for
developing a cell therapy for the front of the eye.
Research objectives
The first objective was to optimise an in vitro injury model mimicking a corneal surface using
human corneal epithelial cells (hCEC) stimulated with various injurious agents. Once optimised
the second objective was to investigate whether CSSC conditioned media and then CSSC in co-
culture could modulate the injury environment. The final objective was to seed CSSC on AM and
investigate whether the CSSC-AM construct provided an anti-inflammatory, healing response to
the injury.
Research methods
Treatment of hCEC with ethanol and pro-inflammatory cytokines were compared in terms of
viability loss, cytotoxicity, and pro-inflammatory cytokine release in order to generate the novel
in vitro injury. Co-culture experiments were performed with CSSC alone and with CSSC-AM
constructs. The effect of injury and co-culture on viability, cytotoxicity, interleukin (IL)-6 and IL-
8 production, and IL1B, TNF, IL6, and CXCL8 mRNA expression were assessed.
Research results
An optimal injury of 20% (v/v) ethanol for 30 s with 1 ng/mL IL-1 beta was developed. Co-
culture of the injury model with CSSC inhibited loss of hCEC viability caused by injury. Enzyme
linked immunosorbent assay and PCR showed a significant reduction in the production of IL-6
and IL-8  pro-inflammatory cytokines  and reduction in  pro-inflammatory cytokine  mRNA
expression during co-culture with CSSC alone and with the AM construct.
Research conclusions
The novel findings of this study confirm the therapeutic potential of the CSSC and the possible
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use of AM as a cell carrier for application to the ocular surface.
Research perspectives
The novel injury model developed in this study can be adapted for studying the therapeutic
effects of many different agents. The findings of this study may lead to the development of
practise changing cell therapies for treatment of inflammatory disorders of the cornea in clinic.
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